Pular para o conteúdo
Afasia primária progressiva
ORPHA:95432CID-11 · 6D83DOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
neuroInício adultaHerança Complex/Unknown
Também conhecida comoPPAAPPDFT

A afasia progressiva primária (APP) é um distúrbio neurodegenerativo, caracterizado por uma dissolução primária da linguagem, com relativa preservação de outras faculdades mentais durante pelo menos os primeiros 2 anos de doença. A PPA é reconhecida como a variante de linguagem no espectro de distúrbios da demência frontotemporal (DFT). A PPA pode ser classificada em 3 subtipos com base em características específicas de fala e linguagem: demência semântica (SD), afasia progressiva não fluente (PNFA) e afasia progressiva logopênica (lv-PPA).

Em construçãohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

💬
EM LINGUAGEM SIMPLES

A afasia primária progressiva é uma condição neurodegenerativa que causa a perda gradual e constante da capacidade de falar e entender a linguagem. Nos primeiros dois anos da doença, outras áreas do pensamento e da memória costumam permanecer relativamente preservadas. A família geralmente percebe que a pessoa tem muita dificuldade em encontrar o nome de palavras comuns ou perde a fluência da comunicação. Ela não possui um Protocolo Clínico e Diretrizes Terapêuticas (PCDT) próprio nem remédios específicos dispensados pelo SUS nos registros oficiais. O acompanhamento deve ser realizado nos serviços neurológicos e multidisciplinares da rede de saúde.

📋
Informacoes curadas por IA — podem conter imprecisoes

A afasia progressiva primária (APP) é um distúrbio neurodegenerativo, caracterizado por uma dissolução primária da linguagem, com relativa preservação de outras faculdades mentais durante pelo menos os primeiros 2 anos de doença. A PPA é reconhecida como a variante de linguagem no espectro de distúrbios da demência frontotemporal (DFT). A PPA pode ser classificada em 3 subtipos com base em características específicas de fala e linguagem: demência semântica (SD), afasia progressiva não fluente (PNFA) e afasia progressiva logopênica (lv-PPA).

Pesquisas ativas
34 ensaios
81 total registrados no ClinicalTrials.gov
Publicações científicas
2.213 artigos
Último publicado: 2026 Apr 16

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
7.0
Worldwide
Início
Adult
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
22 sintomas
👁️
Olhos
1 sintomas
🧬
Pele e cabelo
1 sintomas
🦴
Ossos e articulações
1 sintomas
🫘
Rins
1 sintomas

+ 35 sintomas em outras categorias

Características mais comuns

—
Perseveração
—
Comportamento sexual inapropriado
—
Atrofia cerebral
—
Agnosia visual
—
Anomia
—
EEG com atividade lenta contínua
61sintomas
Sem dados (61)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 61 características clínicas mais associadas, ordenadas por frequência.

PerseveraçãoPerseveration
Comportamento sexual inapropriadoInappropriate sexual behavior
Atrofia cerebralBrain atrophy
Agnosia visualVisual agnosia

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico2.213PubMed
Últimos 10 anos200publicações
Pico2025152 papers
Linha do tempo
2026Hoje · 2026🧪 2007Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

7 genes identificados com associação a esta condição. Padrão de herança: Multigenic/multifactorial, Not applicable.

TREM2Triggering receptor expressed on myeloid cells 2Candidate gene tested inTolerante
VIAS BIOLÓGICAS (4)
DAP12 signalingDAP12 interactionsOther semaphorin interactionsImmunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
MECANISMO DE DOENÇA

Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 2

An autosomal recessive disease characterized by presenile frontal dementia with leukoencephalopathy and basal ganglia calcification. In most cases the disorder first manifests in early adulthood as pain and swelling in ankles and feet, followed by bone fractures. Neurologic symptoms manifest in the fourth decade of life as a frontal lobe syndrome with loss of judgment, euphoria, and disinhibition. Progressive decline in other cognitive domains begins to develop at about the same time. The disorder culminates in a profound dementia and death by age 50 years.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
47.7 TPM
Substância negra
20.1 TPM
Pulmão
17.4 TPM
Nervo tibial
14.5 TPM
Hipotálamo
10.7 TPM
OUTRAS DOENÇAS (8)
polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 2amyotrophic lateral sclerosisprogressive non-fluent aphasiabehavioral variant of frontotemporal dementia
HGNC:17761UniProt:Q9NZC2
GRNProgranulinDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Neutrophil degranulation
MECANISMO DE DOENÇA

Frontotemporal dementia 2

A form of dementia characterized by pathologic finding of frontotemporal lobar degeneration, presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. Gestural apraxia, parkinsonism, visual loss, and visual hallucinations are present in 25 to 40% of patients.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
503.8 TPM
Baço
384.4 TPM
Pulmão
354.8 TPM
Sangue
300.9 TPM
Fibroblastos
292.5 TPM
OUTRAS DOENÇAS (5)
neuronal ceroid lipofuscinosis 11GRN-related frontotemporal lobar degeneration with Tdp43 inclusionssemantic dementiaprogressive non-fluent aphasia
HGNC:4601UniProt:P28799
CHMP2BCharged multivesicular body protein 2bCandidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Late endosomal microautophagy
MECANISMO DE DOENÇA

Frontotemporal dementia and/or amyotrophic lateral sclerosis 7

A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia (FTD) is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis (ALS) is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis. FTDALS7 is an autosomal dominant form characterized by onset of ALS or FTD in adulthood. A few patients may have both phenotypes.

OUTRAS DOENÇAS (5)
frontotemporal dementia and/or amyotrophic lateral sclerosis 7semantic dementiaprogressive non-fluent aphasiaamyotrophic lateral sclerosis
HGNC:24537UniProt:Q9UQN3
MAPTMicrotubule-associated protein tauDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Caspase-mediated cleavage of cytoskeletal proteins
EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
223.0 TPM
Cérebro - Hemisfério cerebelar
218.9 TPM
Córtex cerebral
161.2 TPM
Brain Frontal Cortex BA9
156.7 TPM
Brain Anterior cingulate cortex BA24
104.1 TPM
OUTRAS DOENÇAS (10)
Pick diseaseprogressive supranuclear palsy-parkinsonism syndromesemantic dementiasupranuclear palsy, progressive, 1
HGNC:6893UniProt:P10636
TMEM106BTransmembrane protein 106BCandidate gene tested inTolerante
MECANISMO DE DOENÇA

Frontotemporal dementia 2

A form of dementia characterized by pathologic finding of frontotemporal lobar degeneration, presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. Gestural apraxia, parkinsonism, visual loss, and visual hallucinations are present in 25 to 40% of patients.

EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Endocervix
14.8 TPM
Útero
14.5 TPM
Cervix Ectocervix
14.3 TPM
Glândula adrenal
13.7 TPM
Fallopian Tube
12.2 TPM
OUTRAS DOENÇAS (4)
leukodystrophy, hypomyelinating, 16behavioral variant of frontotemporal dementiaprogressive non-fluent aphasiasemantic dementia
HGNC:22407UniProt:Q9NUM4
VCPTransitional endoplasmic reticulum ATPaseCandidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (10)
AggrephagyAttachment and EntryAttachment and EntryAMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274)ABC-family proteins mediated transport
MECANISMO DE DOENÇA

Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 1

An autosomal dominant disease characterized by disabling muscle weakness clinically resembling to limb girdle muscular dystrophy, osteolytic bone lesions consistent with Paget disease, and premature frontotemporal dementia. Clinical features show incomplete penetrance.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
229.2 TPM
Linfócitos
209.1 TPM
Músculo esquelético
193.2 TPM
Aorta
172.4 TPM
Útero
171.2 TPM
OUTRAS DOENÇAS (10)
frontotemporal dementia and/or amyotrophic lateral sclerosis 6inclusion body myopathy with Paget disease of bone and frontotemporal dementia type 1Charcot-Marie-Tooth disease type 2Yamyotrophic lateral sclerosis
HGNC:12666UniProt:P55072
PSEN1Presenilin-1Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (1)
Neutrophil degranulation
MECANISMO DE DOENÇA

Alzheimer disease 3

A familial early-onset form of Alzheimer disease. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
39.3 TPM
Skin Sun Exposed Lower leg
25.1 TPM
Skin Not Sun Exposed Suprapubic
22.8 TPM
Nervo tibial
20.5 TPM
Fibroblastos
19.7 TPM
OUTRAS DOENÇAS (9)
semantic dementiaPick diseaseAlzheimer disease 3acne inversa, familial, 3
HGNC:9508UniProt:P49768

Variantes genéticas (ClinVar)

259 variantes patogênicas registradas no ClinVar.

🧬 TREM2: NM_018965.4(TREM2):c.491T>A (p.Leu164Ter) ()
🧬 TREM2: NM_018965.4(TREM2):c.428del (p.Phe143fs) ()
🧬 TREM2: NM_018965.4(TREM2):c.41-1G>C ()
🧬 TREM2: NM_018965.4(TREM2):c.114T>G (p.Tyr38Ter) ()
🧬 TREM2: NM_018965.4(TREM2):c.257A>T (p.Asp86Val) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 2 variantes classificadas pelo ClinVar.

1
1
Patogênica (50.0%)
VUS (50.0%)
VARIANTES MAIS SIGNIFICATIVAS
GRN: NM_002087.4(GRN):c.709-2A>G [Pathogenic]
GRN: NM_002087.4(GRN):c.1735C>T (p.Arg579Cys) [Uncertain significance]

Vias biológicas (Reactome)

50 vias biológicas associadas aos genes desta condição.

Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell DAP12 interactions DAP12 signaling Other semaphorin interactions Neutrophil degranulation Budding and maturation of HIV virion Macroautophagy Pyroptosis Endosomal Sorting Complex Required For Transport (ESCRT) HCMV Late Events Late endosomal microautophagy Sealing of the nuclear envelope (NE) by ESCRT-III Translation of Replicase and Assembly of the Replication Transcription Complex Translation of Replicase and Assembly of the Replication Transcription Complex Caspase-mediated cleavage of cytoskeletal proteins Activation of AMPK downstream of NMDARs PKR-mediated signaling Translesion Synthesis by POLH HSF1 activation ABC-family proteins mediated transport N-glycan trimming in the ER and Calnexin/Calreticulin cycle Hedgehog ligand biogenesis Hh mutants are degraded by ERAD Defective CFTR causes cystic fibrosis Josephin domain DUBs Ovarian tumor domain proteases E3 ubiquitin ligases ubiquitinate target proteins Protein methylation Neddylation RHOH GTPase cycle Aggrephagy Attachment and Entry Attachment and Entry KEAP1-NFE2L2 pathway Dengue Virus Genome Translation and Replication AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide Nuclear signaling by ERBB4 Degradation of the extracellular matrix Regulated proteolysis of p75NTR NRIF signals cell death from the nucleus Activated NOTCH1 Transmits Signal to the Nucleus Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants NOTCH2 Activation and Transmission of Signal to the Nucleus EPH-ephrin mediated repulsion of cells NOTCH3 Activation and Transmission of Signal to the Nucleus NOTCH4 Activation and Transmission of Signal to the Nucleus Noncanonical activation of NOTCH3 TGFBR3 PTM regulation

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
✓Aprovado1
2Fase 27
1Fase 18
·Pré-clínico65
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 81 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Afasia primária progressiva

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Onde estão os ensaios

Com ensaio aberto em 10 países. O ponto verde marca onde há vaga agora.

🟢 Recrutando agora

29 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT07650188 · Stimulating the Aging Brain Using Brain and Sensory Stimulat…Recrutando
NA🇺🇸 Estados Unidos
NCT07260253 · Remotely-supervised Neuromodulation in PPARecrutando
NA🇺🇸 Estados Unidos
NCT07219680 · Intervention for Communication Quality of Life in Primary Pr…Recrutando
NA🇺🇸 Estados Unidos
NCT07798700 · Biofluid Research on Age-Related or Inherited Neurodegenerat…Recrutando
🇺🇸 Estados Unidos
NCT07158216 · Long Term Effect of Brain Stimulation in PPARecrutando
NA🇪🇸 Espanha
NCT06613204 · STELLA-FTD: Examination of a Behavior Change Intervention fo…Recrutando
NA🇺🇸 Estados Unidos
NCT06066710 · Propranolol in Primary Progressive AphasiaRecrutando
EARLY_PHASE1🇺🇸 Estados Unidos
NCT06473714 · Effects of Transcranial Direct Current Stimulation (tDCS) on…Recrutando
NA🇫🇷 França
NCT06739967 · Speech and Language Interventions for Italian People With PP…Recrutando
🇮🇹 Itália
NCT06191198 · Communication Bridge 3 StudyRecrutando
PHASE2🇺🇸 Estados Unidos
NCT06511752 · Educational Support Group Program for Bilingual and Spanish-…Recrutando
EARLY_PHASE1🇺🇸 Estados Unidos
NCT05386394 · Transcranial Direct Current Stimulation in the Treatment of …Recrutando
PHASE2🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT06529744 · Improving Prognostic Confidence in Neurodegenerative Disease…Recrutando
🇨🇦 Canadá
NCT06064890 · A Study to Evaluate the Safety and Effect of AVB-101, a Gene…Recrutando
PHASE1, PHASE2🇧🇪 Bélgica · 🇨🇦 Canadá · 🇮🇹 Itália +6
NCT05741853 · Cognitive Reserve and Response to Speech-Language Interventi…Recrutando
NA🇪🇸 Espanha · 🇺🇸 Estados Unidos
NCT05800028 · Memory and Social InteractionsRecrutando
🇫🇷 França
NCT05443633 · Enhancing Language Function in AphasiaRecrutando
NA🇺🇸 Estados Unidos
NCT03887481 · Targeting Language-specific and Executive-control Networks W…Recrutando
NA🇺🇸 Estados Unidos
NCT04957537 · Semantic Rehabilitation for Patients With Primary Progressiv…Recrutando
NA🇫🇷 França
NCT04920318 · Enhancing Language Function in Primary Progressive AphasiaRecrutando
NA🇺🇸 Estados Unidos
NCT04715399 · UPenn Observational Research Repository on Neurodegenerative…Recrutando
🇺🇸 Estados Unidos
NCT04363684 · ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration…Recrutando
🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT01818661 · Longitudinal Multi-Modality Imaging in Progressive Apraxia o…Recrutando
PHASE4🇺🇸 Estados Unidos
NCT03313011 · The Neurobiology of Two Distinct Types of Progressive Apraxi…Recrutando
🇺🇸 Estados Unidos
NCT00537004 · Language in Primary Progressive AphasiaRecrutando
🇺🇸 Estados Unidos
NCT06921265 · Targeted Transcranial Magnetic Stimulation to Improve Langua…Por convite
NA🇮🇹 Itália
NCT05901233 · Speech-Language Treatment With Remotely Supervised Transcran…Por convite
NA🇺🇸 Estados Unidos
NCT06649084 · Primary Progressive Aphasia Multicomponent Language Treatmen…Por convite
NA🇺🇸 Estados Unidos
NCT07567664 · Tracking and Predicting How Brain Damage Spreads in Neurodeg…Por convite
NA🇮🇹 Itália

Outros ensaios clínicos

81 ensaios clínicos encontrados, 34 ativos.

Distribuição por fase
NCT07033481 · Clinical Study of Neflamapimod in Patients With Primary Prog…Ativo
PHASE2🇬🇧 Reino Unido · 🇺🇸 Estados Unidos
NCT06211374 · Communication Bridge Pilot StudyAtivo
NA🇺🇸 Estados Unidos
NCT06870838 · Neuroinflammation in FTLDAtivo
🇳🇱 Países Baixos
NCT05368350 · Treating Primary Progressive Aphasia and Apraxia of Speech U…Ativo
NA🇺🇸 Estados Unidos
NCT04881617 · Treatment for Speech and Language in Primary Progressive Aph…Ativo
NA🇺🇸 Estados Unidos
NCT05860647 · Transmagnetic Stimulation Pilot in Primary Progressive Aphas…Concluído
NA🇺🇸 Estados Unidos
NCT06181500 · Home-Based Exercise in Primary Progressive Aphasia (HEPPA)Concluído
NA🇨🇦 Canadá
NCT05437159 · Investigating Speech Sequencing in Neurotypical Speakers and…Concluído
NA🇺🇸 Estados Unidos
NCT05842473 · Long-term Effect of TMS in Primary Progressive AphasiaConcluído
NA🇪🇸 Espanha
NCT05615922 · Remotely Supervised Transcranial Direct Current Stimulation …Concluído
PHASE2🇺🇸 Estados Unidos
NCT05537688 · Identification of Graphic Markers of Neurocognitive Disorder…Concluído
🇨🇦 Canadá
NCT05525377 · Better Living With Non-memory-led DementiaConcluído
NA🇬🇧 Reino Unido
NCT04188067 · TMS for the Treatment of Primary Progressive AphasiaConcluído
NA🇺🇸 Estados Unidos
NCT04939818 · Clinical Feasibility of Speech Phenotyping for Remote Assess…Concluído
🇬🇧 Reino Unido
NCT05697380 · CB3 Pilot (Communication Bridge: A Person-centered Internet-…Concluído
NA🇺🇸 Estados Unidos
NCT04566731 · Treating Primary Progressive Aphasia (PPA) Using tDCSConcluído
NA🇺🇸 Estados Unidos
NCT04046991 · Treating Primary Progressive Aphasia (PPA) Using High-defini…Concluído
PHASE2🇺🇸 Estados Unidos
NCT04412083 · PPA Tele-Savvy: A Pilot Study of an Online Intervention for …Concluído
NA🇺🇸 Estados Unidos
NCT04431401 · rTMS Treatment of Primary Progressive AphasiaConcluído
NA🇨🇳 China
NCT03805659 · HDtDCS in Logopenic Variant PPA: Effects on Language and Neu…Concluído
NA🇺🇸 Estados Unidos
NCT04187391 · The Effects of a Multimodal Approach for the Treatment of PP…Concluído
NA🇮🇹 Itália
NCT03406429 · rTMS as a Treatment for PPAConcluído
EARLY_PHASE1🇺🇸 Estados Unidos
NCT03728582 · Rehabilitating and Decelerating Language Loss in Primary Pro…Concluído
NA🇺🇸 Estados Unidos
NCT04045990 · Network Modulation in Alzheimer's DiseaseConcluído
NA🇺🇸 Estados Unidos
NCT04720001 · Florbetaben PET Imaging in PPAConcluído
🇺🇸 Estados Unidos
NCT03371706 · Communication Bridge 2Concluído
NA🇺🇸 Estados Unidos
NCT03580954 · Transcranial Magnetic Stimulation in Primary Progressive Aph…Concluído
NA🇪🇸 Espanha
NCT02928848 · Transcranial Direct Current Stimulation for Primary Progress…Concluído
NA🇺🇸 Estados Unidos
NCT03076671 · More Than a Movement Disorder: Applying Palliative Care to P…Concluído
NA🇺🇸 Estados Unidos
NCT02736695 · Assessment of Hyperphosphorylated Tau PET Binding in Primary…Concluído
PHASE1🇺🇸 Estados Unidos
NCT02541097 · Preventing Language Decline in DementiaConcluído
NA🇨🇦 Canadá
NCT03153371 · Early-onset Alzheimer's Disease Phenotypes: Neuropsychology …Concluído
🇺🇸 Estados Unidos
NCT03283449 · Tau PET Imaging in Atypical DementiasConcluído
PHASE1🇺🇸 Estados Unidos
NCT02966145 · 4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2Concluído
🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT02365922 · Advancing Research and Treatment for Frontotemporal Lobar De…Concluído
🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT02606422 · tDCS Intervention in Primary Progressive AphasiaConcluído
NA🇺🇸 Estados Unidos
NCT02439853 · Communication Bridge Speech Therapy Research StudyConcluído
NA🇺🇸 Estados Unidos
NCT01723553 · Amyloid-related Imaging Abnormalities (Microbleeds) in Atypi…Concluído
PHASE1🇺🇸 Estados Unidos
NCT04726527 · Clinical Evaluation of Florbetapir in Primary Progressive Ap…Concluído
🇺🇸 Estados Unidos
NCT02675270 · Rehabilitation and Prophylaxis of Anomia in Primary Progress…Concluído
NA🇺🇸 Estados Unidos
NCT01465360 · Performance of AclarusDx™, a Blood-Based Transcriptomic Test…Concluído
🇺🇸 Estados Unidos
NCT01623284 · PiB PET Scanning in Speech and Language Based DementiasConcluído
PHASE1🇺🇸 Estados Unidos
NCT00957710 · Language Treatment for Progressive AphasiaConcluído
NA🇨🇦 Canadá
NCT05730023 · A Multimodal Approach for Clinical Diagnosis and Treatment o…UNKNOWN
NA🇮🇹 Itália
NCT04193267 · Can Magnetic Brain Stimulation Improve Language Function in …UNKNOWN
NA🇨🇦 Canadá
NCT03174886 · A 24-month Phase 1 Pilot Study of AADvac1 in Patients With N…UNKNOWN
PHASE1🇩🇪 Alemanha
NCT05978804 · Home-based tDCS in Frontotemporal Dementia or Alzheimer's Di…Encerrado
NA🇺🇸 Estados Unidos
NCT05742698 · Nabilone for Agitation in Frontotemporal DementiaEncerrado
PHASE2🇨🇦 Canadá
NCT04290988 · Circuitry Assessment and Reinforcement Training Effects on R…Encerrado
NA🇺🇸 Estados Unidos
NCT06711510 · Predict to Prevent PGRN DiseaseCancelado
NA
NCT03448133 · rTMS for the Treatment of Primary Progressive Aphasia: A Ran…Cancelado
NA
NCT04486586 · Effects of tDCS on Apraxia of Speech in Non-Fluent Primary P…Cancelado
NA🇺🇸 Estados Unidos
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
1.604 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 1.604

#1

Frontotemporal lobar degeneration complexity: atypical presentations and heterogeneous proteinopathies in five cases.

Frontiers in neuroscience2026

Frontotemporal lobar degeneration (FTLD) encompasses heterogeneous clinical syndrome within the frontotemporal spectrum, where clinicopathological associations may be misleading. This case series illustrates clinicopathological variability and mismatches. A retrospective case series was conducted within the brain donation program at the Golgi Cenci Foundation. Cases presenting at onset with a frontotemporal-spectrum phenotype, longitudinal clinical data, and post-mortem neuropathological characterization were included. Five cases (mean age at onset 65.4 years) were clinically diagnosed with major neurocognitive disorder due to frontotemporal dementia (FTD). Neuropathological examination revealed clinicopathological heterogeneity: two cases showed FTLD-TDP-A associated with GRN mutations, including a classic case and one with posterior (parieto-occipital) involvement; one non-fluent variant primary progressive aphasia (nfvPPA) case demonstrated FTLD-TDP-A with multiple co-pathologies; one semantic-variant-like case was driven by high Alzheimer's disease neuropathological changes; and one behavioral variant FTD-like case corresponded to frontal-variant Alzheimer's disease (fvAD) with extensive mixed pathology, including Lewy body disease, LATE-NC, and vascular pathology. Findings indicate that clinical phenotypes are more influenced by the anatomical distribution of pathology than by the specific molecular substrate. Frequent coexisting proteinopathies and asymmetric involvement contribute to phenotypic variability, reinforcing the role of neuropathological examination of both hemispheres for accurate clinicopathological correlations and definitive etiological diagnosis.

#2

[A case of progressive supranuclear palsy with progressive non-fluent agrammatic variant primary progressive aphasia who could sing fluently].

Rinsho shinkeigaku = Clinical neurology2026 Mar 14

The patient was a 65-year-old man. He visited the hospital complaining of gait disturbances and difficulty speaking. He was diagnosed with progressive supranuclear palsy because of slow vertical eye movements, frequent falls, and freezing gait; these symptoms were levodopa-resistant. The patient also had aphasia similar to non-fluent agrammatic variant of primary progressive aphasia, stuttering, and palilalia. However, he was able to sing a familiar song fluently. In contrast, for an unfamiliar song, he could not begin singing without the lyrics, and was more accurate at reading aloud than singing. Nonfluent aphasia with preserved singing ability has been reported in patients with stroke and trauma. However, this has rarely been reported for neurodegenerative diseases. This phenomenon may be due to the functional preservation of the right hemisphere and the left temporal lobe. The familiar song may have been stored in long-term memory as a set of lyrics and melody, and he may have produced it as automatic language.

#3

Enhanced diagnostic interpretation of the MoCA using machine learning.

Frontiers in neuroscience2026

Artificial Intelligence (AI) is increasingly being integrated into clinical practice to optimize diagnosis in neurocognition. By capturing distinct cognitive signatures, this approach may offer a more precise alternative to the traditional interpretation of the Montreal Cognitive Assessment (MoCA) which often relies on a fixed cutoff score (26/30). We aimed to evaluate whether machine learning models, by integrating detailed MoCA subtest scores, demographic variables, and cognitive chart-derived metrics, can improve the detection of cognitive impairment and classification of dementia subtypes. We analyzed 38,746 clinical observations (17,188 unique individuals) from the National Alzheimer's Coordinating Center database. Five supervised learning algorithms, Extreme Gradient Boosting (XGBoost), Random Forest, Support Vector Machine (SVM), Logistic Regression, and k-Nearest Neighbors (KNN), were trained using detailed MoCA subtest scores, demographic variables, and cognitive chart-derived metrics as predictors. To ensure generalizability of results and prevent data leakage, we applied a rigorous nested Repeated Grouped Cross-Validation strategy. Decision thresholds were optimized via the Youden Index on independent calibration sets, and model interpretability was ensured through SHAP value analysis. Machine learning models consistently outperformed conventional approach. For the global detection of cognitive impairment, XGBoost achieved the best performance (Youden Index 0.61 vs. 0.54 for the standard cutoff). Regarding subtype classification, models demonstrated variable discriminative capacity depending on clinical homogeneity: primary progressive aphasia was best classified (Youden ≈ 0.77), followed by Lewy body dementia and Alzheimer's disease, while vascular dementia remained more challenging to isolate. Feature importance analysis highlighted the Cognitive Quotient as a robust universal predictor, while pinpointing disease-specific drivers such as delayed recall for Alzheimer's disease and verbal fluency for primary progressive aphasia. Our findings suggest interpretable machine learning enhances diagnostic utility of the MoCA, yielding superior accuracy compared to a fixed cutoff. By synthesizing individualized subtest profiles within a transparent framework, this approach offers a clinically actionable solution. It transforms the MoCA from a simple screening tool to a precision diagnostic aid, optimizing patient triage in the era of disease-modifying therapies.

#4

White Matter Hyperintensities in Behavioral Variant Frontotemporal Dementia and Semantic Variant Primary Progressive Aphasia.

Neurology open access2026 Mar

White matter hyperintensities (WMH) in patients with cerebrovascular risk factors (CVRF), are often linked to cerebral vascular changes, but can be caused by genetic variants selectively targeting white matter. In addition, WMH can be present in neurodegenerative disorders such as frontotemporal lobar degeneration (FTLD) and are linked to some FTLD genetic variants. This study aims to investigate WMH burden in patients with behavioral variant frontotemporal dementia (bvFTD) and semantic variant primary progressive aphasia (svPPA) versus controls and to evaluates the influence of CVRF. This cross-sectional retrospective analysis examined individuals meeting research diagnostic criteria for bvFTD and svPPA with high-quality structural MRI at the UCSF Memory and Aging Center between September 2008 and December 2021. WMH burden and spatial distribution were assessed by disease group compared to age- and sex-matched controls and associations with CVRF evaluated. We included 109 individuals with bvFTD [mean age (SD) 62.9 (8.6), 40% female], 47 with svPPA [mean (SD) age 65.4 (7.5), 51% female], and matched controls. After adjusting for age, apolipoprotein E4 (APOE-ε4) status and intracranial volume (ICV), both disease groups had higher WMH burden compared to controls (bvFTD, R 2 =0.184, p=0.001 and svPPA, R 2 =0.323, p=<0.001). Compared to controls, bvFTD group had more prevalent WMH in the frontal lobe (β=0.403 ; 95% CI 0.27 to 0.54 , p=<0.001), while those with svPPA had more prevalent WMH in the frontal (β=0.462 ; 95% CI 0.26 to 0.66, p <0.001), parietal (β=0.772 ; 95% CI 0.50 to 1.04, p <0.001), temporal (β=0.674 ; 95% CI 0.44 to 0.91, p <0.001), occipital lobes (β=0.364 ; 95% CI 0.14 to 0.59, p=0.002), and corpus callosum (β=0.342 ; 95% CI 0.13 to 0.55, p=0.002). In disease groups, WMH were not significantly associated with CVRF (F=0.468, df=2, p=0.641) suggesting a potential role of non-vascular mechanisms. We did not identify associations between the pathogenic C9orf72 hexanucleotide repeat expansions (HRE) and WMH in bvFTD patients. bvFTD and svPPA are associated with elevated WMH burden independent of CVRF. In bvFTD, WMH are primarily distributed within the frontal lobes, while svPPA shows widespread distribution across lobes. Study limitations include its retrospective, single-center design and limited power for genetic subgroup analyses.

#5

Transcriptomic signature of frontotemporal lobar degeneration with TDP-43 type C pathology.

Brain : a journal of neurology2026 Mar 06

Semantic variant of primary progressive aphasia is a clinical subtype of frontotemporal lobar degeneration and is marked by TDP-43 subtype C pathology (FTLD-TDP C). It is a sporadic disease, yet has a strikingly homogeneous clinicopathological presentation, suggesting a common pathophysiology. The aim of this study was to discover dysregulated pathways in FTLD-TDP C through transcriptomics of the temporal cortex, its most affected region. Bulk RNA sequencing was conducted on temporal cortices of a post-mortem cohort of 18 FTLD-TDP C patients and 23 sex- and age-matched controls. Differential expression and functional analyses were run to detect differentially expressed genes with FDR<0.05 (DEG) and functionally annotate them. We assessed enrichment of TARDBP's protein interactors and RNA targets in DEG. Our findings were compared to other published RNA sequencing data of tauopathies (Alzheimer's dementia, progressive supranuclear palsy and FTLD with MAPT), FTLD-TDP (subtypes A&B) and available proteomics of this cohort. Furthermore, we performed weighted gene co-expression network analysis (WGCNA). We adjusted for differences in cell type composition between cases and controls using cell deconvolution, and removed genes dysregulated in temporal cortices of other datasets. In DEG of FTLD-TDP we focused on enrichment of synaptic processes using SynGO. We found upregulation of damage response, cell structure, RNA splicing processes and downregulation of synaptic processes in 6322 DEG and five disease-related WGCNA modules. TARDBP-related genes were enriched in DEG. Additionally, transmembrane transport across the neurovascular unit was dysregulated. After cell deconvolution and removal of common tau-genes, postsynaptic processes remained dysregulated, specifically gene ontology terms 'modulation of chemical synaptic transmission' and 'neurotransmitter receptor localisation to postsynaptic specialisation membrane'. We found eleven synaptic FTLD-TDP C-specific genes affected on both RNA- and protein-level in the temporal cortex, which were involved in synaptic adhesion (CADM1, NCAN), signal transmission (COMT, RGS144, SLC1A2, TUBB2B) and synaptic plasticity (BEGAIN, ITPKA, LRFN1, RAB3B, SYNPO). In conclusion, a wide range of processes were dysregulated on RNA-level in the temporal cortex of FTLD-TDP C, including commonly affected processes in neurodegeneration, such as structural cell alterations. Dysregulation of TARDBP-related genes and RNA splicing has also been observed in other TDP-43 proteinopathies. Importantly, we found that postsynaptic processes were downregulated in FTLD-TDP C, after removing tauopathy-related genes and after cell deconvolution. In particular, assembly of receptors at the postsynaptic membrane and synaptic signal transmission were affected, both on RNA and protein level. Future research on these pathways could elucidate distinct pathophysiological mechanisms and guide targeted clinical approaches.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC1.226 artigos no totalmostrando 198

2026

Identifying neuropathologic disease in primary progressive aphasia using narrative speech.

Alzheimer's &amp; dementia : the journal of the Alzheimer's Association
2026

Online comprehension of verbal time reference in primary progressive aphasia: Evidence from eyetracking.

Journal of neurolinguistics
2026

Unveiling discrepancies in depression detection among persons with dementia: A comparative analysis of caregiver and self-report.

Journal of Alzheimer's disease : JAD
2026

Frontotemporal lobar degeneration complexity: atypical presentations and heterogeneous proteinopathies in five cases.

Frontiers in neuroscience
2026

[A case of progressive supranuclear palsy with progressive non-fluent agrammatic variant primary progressive aphasia who could sing fluently].

Rinsho shinkeigaku = Clinical neurology
2026

Improving aphasia with daily sessions of tDCS: an open-label study coupled to high-density EEG.

Brain stimulation
2026

Enhanced diagnostic interpretation of the MoCA using machine learning.

Frontiers in neuroscience
2026

White Matter Hyperintensities in Behavioral Variant Frontotemporal Dementia and Semantic Variant Primary Progressive Aphasia.

Neurology open access
2026

Eligibility for Anti-Amyloid-β Monoclonal Antibodies in Patients With Primary Progressive Aphasia due to Alzheimer's Disease in Japan.

Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society
2026

Transcriptomic signature of frontotemporal lobar degeneration with TDP-43 type C pathology.

Brain : a journal of neurology
2026

'I Am No Longer Anxious When I Speak': Experiences of People with Primary Progressive Aphasia Taking Part in a Biographic-Narrative Therapy (Cope PPA).

Brain sciences
2026

Your Mileage May Vary: Individuals with Primary Progressive Aphasia Differ Widely in Their Utilization of Congruent Prosodic and Visual Information During Sentence Comprehension.

Brain sciences
2026

Neurostimulation with Naming Therapy for Primary Progressive Aphasia: A Pilot Study Targeting Transcranial Direct Current (tDCS) Stimulation for the Individual.

Brain sciences
2026

Incidence and Survival Rates of Frontotemporal Lobar Degeneration: Population-Based Registry Study.

Neurology
2026

Advanced neuroimaging assessment of neurodegenerative dementia syndromes: A framework for comprehensive multimodal FDG-PET, MR-perfusion, and MR-diffusion analysis.

NeuroImage. Clinical
2026

Mixed primary progressive aphasia and alcohol use disorder: a case of detailed clinical phenotyping outperforming molecular imaging.

Neurocase
2026

Morphometric features enhance phenotype discrimination in frontotemporal lobar degeneration.

Brain communications
2026

Real-world evaluation of Armstrong's criteria in corticobasal degeneration: Phenotypic overlap and diagnostic challenges.

Parkinsonism &amp; related disorders
2026

Repetitive behaviors in syndromes associated with frontotemporal lobar degeneration.

Journal of Alzheimer's disease : JAD
2026

"Not That I've Become Exceptional, But I'm Able to Make Myself Understood Better": Impact of Speech and Language Therapy on Everyday Communication in People with Primary Progressive Aphasia and Their Carers.

Neurology and therapy
2026

A Single-Item Screening Tool for the Assessment of Hoarding: Preliminary Observations.

The Journal of neuropsychiatry and clinical neurosciences
2026

Multimodal semantic knowledge of emotion concepts in frontotemporal dementia.

medRxiv : the preprint server for health sciences
2026

Gamma tACS as a novel treatment for primary progressive aphasia: A pilot case series of four cases.

Brain stimulation
2026

Mixed Nonfluent/Agrammatic Primary Progressive Aphasia and Behavioral Variant Frontotemporal Dementia: A Case Report From Tanzania.

Alzheimer disease and associated disorders
2026

"Doing the Best I Can": Qualitative Outcomes and Participant Feedback From a Combined Communication and Counselling Treatment for Primary Progressive Aphasia.

International journal of language &amp; communication disorders
2026

Noninvasive Brain Stimulation in Translational Cognitive Neuroscience-Applications in Aphasia and Beyond: 2025 H. Houston Merritt Award Lecture.

Neurology
2026

Treatment Efficacy of Semantic Feature Analysis in Logopenic and Semantic Variants of Primary Progressive Aphasia.

Healthcare (Basel, Switzerland)
2025

Two Languages and One Aphasia: A Systematic Scoping Review of Primary Progressive Aphasia in Chinese Bilingual Speakers, and Implications for Diagnosis and Clinical Care.

Brain sciences
2026

Patterns and Trajectories of Behavioral and Neuropsychiatric Symptoms in Frontotemporal Dementia and Primary Progressive Aphasia.

Neurology
2026

Behavioral and Neuropsychiatric Symptoms in Patients With Frontotemporal Dementia and Primary Progressive Aphasia.

Neurology
2026

Potential role of MRI to optimize clinical trial design for progressive supranuclear palsy and corticobasal degeneration.

The journal of prevention of Alzheimer's disease
2025

Automatic Detection of Articulatory-Based Disfluencies in Primary Progressive Aphasia.

IEEE journal of selected topics in signal processing
2026

Automated item-level measures of verbal fluency in semantic and logopenic primary progressive aphasia.

Alzheimer's &amp; dementia : the journal of the Alzheimer's Association
2026

Effect of Transcranial Direct Current Stimulation on Motor Speech in Nonfluent Primary Progressive Aphasia: A Case Report.

Case reports in neurology
2026

Depression and apathy in frontotemporal dementia: a short assessment of facts and outlook.

Journal of neural transmission (Vienna, Austria : 1996)
2026

Understanding the multifaceted nature of quality of life in dementia using a transdiagnostic network analysis approach.

Aging &amp; mental health
2026

[What are important goals in the treatment of people with primary progressive aphasia?].

Fortschritte der Neurologie-Psychiatrie
2026

Logopenic variant of primary progressive aphasia in a bilingual non-Alzheimer's disease octogenarian.

Dementia &amp; neuropsychologia
2026

Subjective time perception in dementia: a behavioural and neuroanatomical analysis.

Brain communications
2026

Baseline Functional Connectivity Predicts Who Will Benefit From Neuromodulation: Evidence From Primary Progressive Aphasia.

Neurorehabilitation and neural repair
2025

Effectiveness of a teletherapy-based phonological short-term memory training in reducing phonological impairments in the logopenic variant of primary progressive aphasia: a multiple case study.

Frontiers in human neuroscience
2025

Applicability and Correlates of a Symptom-Led Staging System for Primary Progressive Aphasia.

European journal of neurology
2025

Rethinking the diagnosis of primary progressive aphasia: current challenges and future directions.

Frontiers in aging neuroscience
2025

The Progressive Aphasia Communication Toolkit (PACT): A Strengths-Based Approach to Multidomain Evaluation for Intervention.

medRxiv : the preprint server for health sciences
2025

MULTI-OBJECT DATA INTEGRATION IN THE STUDY OF PRIMARY PROGRESSIVE APHASIA.

The annals of applied statistics
2026

Cognitive-linguistic skills in production of expository discourse: Insights from longitudinal changes and neural correlates in primary progressive aphasia.

Cortex; a journal devoted to the study of the nervous system and behavior
2026

Peripheral inflammation in a Canadian cohort of neurodegenerative conditions: Occurrence, determinants, and impact.

Journal of Alzheimer's disease : JAD
2025

Putative mitochondrial components of frontotemporal lobar degeneration: topological correlations between mitochondrial density and atrophy in FTLD/FTD phenotypes.

Journal of neurology
2025

Frontotemporal dementia characterization using neurite orientation dispersion and density imaging.

Brain communications
2025

Computed tomography-based nnU-Net for region-specific brain structural changes across the alzheimer's continuum and frontotemporal dementia subtypes.

Scientific reports
2025

Classifying and Monitoring Primary Progressive Aphasia in the Greek Population: A "Mini Linguistic State Examination (MLSE)" Tool.

Medicina (Kaunas, Lithuania)
2025

Targeting Executive Function and Language Impairments with tACS Combined with Behavioral Intervention in Primary Progressive Aphasia: A Case-Series, Pilot Investigation.

Brain sciences
2025

Exploring Language Impairment in Catalan-Dominant Bilinguals with Primary Progressive Aphasia: Preliminary Data.

Brain sciences
2025

Speaking in Tones: The role of lexical tones in Chinese-speaking Primary Progressive Aphasia.

medRxiv : the preprint server for health sciences
2025

Agentic Generative Artificial Intelligence System for Classification of Pathology-Confirmed Primary Progressive Aphasia Variants.

medRxiv : the preprint server for health sciences
2025

The influence of bilingualism on the assessment and treatment of an Italian-English speaker with the logopenic variant of PPA.

Research square
2025

Functional network collapse in neurodegenerative disease.

Nature communications
2025

Predictors of Spelling and Reading Performance in Logopenic Variant Primary Progressive Aphasia.

Journal of speech, language, and hearing research : JSLHR
2025

Social cognition in the nonfluent and logopenic variants of primary progressive aphasia: A review of variant-specific profiles.

Cortex; a journal devoted to the study of the nervous system and behavior
2025

The use of discourse particles in oral picture description by individuals with primary progressive aphasia.

Cortex; a journal devoted to the study of the nervous system and behavior
2026

Patterns of cortical atrophy are associated with specific cognitive domains in patients with logopenic primary progressive aphasia.

Journal of Alzheimer's disease : JAD
2025

Anterior temporal lobe, word comprehension, and physiology of atrophy in semantic primary progressive aphasia.

Neurocase
2025

The genetic landscape of frontotemporal lobar degeneration: investigation of a diagnostic cohort of 2747 probands.

Brain : a journal of neurology
2025

A multilingual assessment approach in aphasia: Evidence from three Spanish-English speakers with primary progressive aphasia.

Clinical linguistics &amp; phonetics
2025

Language and psychiatric symptom overlap in FTD: an SLP perspective.

International review of psychiatry (Abingdon, England)
2025

Dysgraphia in Japanese patients with primary progressive aphasia.

Brain and language
2025

Distinguishing Among Variants of Primary Progressive Aphasia with a Brief Multimodal Test of Nouns and Verbs.

Brain sciences
2025

The emotional journey through the stages of primary progressive aphasia: seven co-produced care pathway recommendations for clinical practice.

Brain impairment : a multidisciplinary journal of the Australian Society for the Study of Brain Impairment
2025

Psycholinguistic Variables and Spelling Accuracy for People with Logopenic Variant Primary Progressive Aphasia: A Cross-Sectional Study.

Aphasiology
2025

Face and Content Validation of the 10-Item Communicative Participation Item Bank General Short Form for Primary Progressive Aphasia: A Cognitive Interviewing Study.

American journal of speech-language pathology
2025

Neuroimaging of vacuolar tauopathy: Response to letter.

Alzheimer's &amp; dementia : the journal of the Alzheimer's Association
2025

Multidimensional cognitive deficits in the typical and atypical variants of Alzheimer's disease.

Alzheimer's research &amp; therapy
2025

Clinical Manifestations and Neural Basis of Semantic Dementia: Converging Evidences From Brain Imaging Studies.

Clinical interventions in aging
2026

Verbal learning in logopenic variant Primary Progressive Aphasia: An EEG investigation.

Neurobiology of aging
2025

TBK1 mutation and its role in frontotemporal dementia and amyotrophic lateral sclerosis in Brazilian families.

Dementia &amp; neuropsychologia
2025

Leveraging language and cognitive data for PPA subtyping: A systematic review of AI-based approaches.

Progress in neuro-psychopharmacology &amp; biological psychiatry
2025

Regional CSF volume quantification using deep learning for comparative analysis of brain atrophy in frontotemporal dementia subtypes.

Frontiers in aging neuroscience
2025

Atypical Semantic Variant Primary Progressive Aphasia With Right Temporal Atrophy in an Ambidextrous Older Adult.

Geriatrics &amp; gerontology international
2025

High-definition brain stimulation targeting separate regions leads to differential word retrieval outcomes in patients with primary progressive aphasia: a pilot study.

Frontiers in neurology
2025

Atrophy progression in frontotemporal lobar degeneration-TDP-C with primary progressive aphasia.

Brain : a journal of neurology
2025

Disentangling phonology from phonological short-term memory in Alzheimer's disease phenotypes.

Alzheimer's research &amp; therapy
2025

Adaptation of Better Conversations with Primary Progressive Aphasia to Norwegian.

Brain sciences
2025

Optical coherence tomography as a potential biomarker for the logopenic variant of primary progressive aphasia: A cross-sectional prospective study.

Alzheimer's &amp; dementia (Amsterdam, Netherlands)
2025

Leveraging Thematic Relationships Between Verbs and Nouns for Noun Retrieval Treatment in Logopenic Primary Progressive Aphasia: A Case Series.

American journal of speech-language pathology
2025

Everyday functioning in young onset dementia: differences between diagnostic groups.

Alzheimer's &amp; dementia : the journal of the Alzheimer's Association
2025

The presymptomatic and early manifestations of semantic dementia.

Brain : a journal of neurology
2025

Written picture descriptions distinguish variants of primary progressive aphasia.

Journal of Alzheimer's disease : JAD
2025

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology
2025

Influence of Speech and Language Therapy on Quality of Life in People With Primary Progressive Aphasia: A Scoping Review.

International journal of language &amp; communication disorders
2025

Effects of Cognitive Demand and Imaginability on Semantic Cognition in Patients with Primary Progressive Aphasia.

Current Alzheimer research
2025

Acoustic Analysis of Apraxia of Speech in a Japanese Patient With Nonfluent/Agrammatic Variant Primary Progressive Aphasia: A Case Study.

Cureus
2025

Neurodevelopment and neural environment inform Alzheimer's disease age at onset and phenotype.

Alzheimer's &amp; dementia : the journal of the Alzheimer's Association
2025

Semi-spontaneous language production in Dutch-speaking individuals with primary progressive aphasia.

Cognitive neuropsychology
2025

Acoustically Altered Speech Perception in Frontotemporal Dementia Syndromes.

Neurology
2025

Incidence and Prevalence of Frontotemporal Dementia: A Systematic Review and Meta-Analysis.

JAMA neurology
2025

Distinctive Progression Patterns of Brain Structural Damage Aid Classification of Frontotemporal Dementia Variants.

European journal of neurology
2025

Protocol for a multisite study on the efficacy of transcranial direct current stimulation as an adjuvant to naming and spelling therapy in the treatment of oral and written naming in individuals with primary progressive aphasia.

Frontiers in human neuroscience
2025

Better Living with Non-memory-led Dementia: study protocol for a randomised controlled trial of a web-based caregiver educational programme (BELIDE trial).

BMJ open
2025

A multi-modal approach for the treatment of non-fluent/agrammatic variant of Primary Progressive Aphasia.

Brain communications
2025

Aphasia Leading to the Diagnosis of Myotonic Dystrophy Type 1: A Case Report.

Cureus
2025

Criminal minds in dementia: A systematic review and quantitative meta-analysis.

Translational psychiatry
2025

Efficacy of Transcranial Magnetic Stimulation and Transcranial Direct-Current Stimulation in Primary Progressive Aphasia Treatment: A Review.

Brain sciences
2025

A spouse's perspective on communication breakdowns and supportive strategies for semantic variant primary progressive aphasia.

Aphasiology
2025

Picture Description and Functional Communication Rating Correlates in Variants of Primary Progressive Aphasia.

Aphasiology
2025

Striatal dopaminergic patterns and clinical features in frontotemporal dementia.

Brain communications
2025

Efficacy of Transcranial Direct Current Stimulation in Patients with Primary Progressive Aphasia: A Systematic Review and Updated Meta-analysis.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Participatory Development of a Speech-Language Telerehabilitation Intervention Combined With Home-Based Transcranial Direct Current Stimulation for Primary Progressive Aphasia: A Qualitative Study.

American journal of speech-language pathology
2025

Co-morbid seizures in frontotemporal dementia: What do they tell us?

Epilepsy research
2025

Longitudinal evaluation of common and unique brain-networks in variants of primary progressive aphasia.

Alzheimer's research &amp; therapy
2025

Connectivity as a universal predictor of tau progression in atypical Alzheimer's disease.

Brain : a journal of neurology
2025

Valence as principal dimension of the semantic space in primary progressive aphasia semantic variant.

Brain communications
2025

Application of machine learning and temporal response function modeling of EEG data for differential diagnosis in primary progressive aphasia.

Scientific reports
2025

Long-Term Therapy With Transcranial Magnetic Stimulation in Primary Progressive Aphasia: A Randomized Clinical Trial.

JAMA network open
2026

How artificial intelligence is shaping neuropsychology: A focus on cognitive assessment of neurodegenerative disorders.

Journal of neuropsychology
2025

Understanding Indirect Speech in Frontotemporal Dementia and Alzheimer's Disease Dementia: Validation of the Hinting Task - Dutch Version (HT-NL).

Journal of the International Neuropsychological Society : JINS
2025

Spatial and Temporal Progression of Neurodegeneration in Confirmed and Suspected TDP-43 Type C Pathology.

Imaging neuroscience (Cambridge, Mass.)
2025

Neurodevelopmental Vulnerability in Alzheimer's Disease and Frontotemporal Dementia.

European journal of neurology
2025

Beyond language: empathy and emotion recognition deficits in primary progressive aphasias.

NeuroImage. Clinical
2025

Frontal Variant Alzheimer's Disease or Primary Psychiatric Disorder? A Case Report.

Reports (MDPI)
2025

Feasibility of Home-Based Transcranial Direct Current Stimulation with Telerehabilitation in Primary Progressive Aphasia-A Case Series.

Brain sciences
2025

Coping With Primary Progressive Aphasia: Factors Predicting Caregiver Psychological Wellbeing and Burden.

International journal of language &amp; communication disorders
2025

Comprehensive intervention combining group and personalized language therapy in primary progressive aphasia: Quantitative and qualitative findings.

Alzheimer's &amp; dementia (New York, N. Y.)
2026

Clinical Translation of Integrated PET-MRI for Neurodegenerative Disease.

Journal of magnetic resonance imaging : JMRI
2025

Clinicopathological characterization of vacuolar tauopathy associated with VCP D395G.

Alzheimer's &amp; dementia : the journal of the Alzheimer's Association
2025

Modulating language and executive functions in bilingual aphasia with cerebellar tDCS: a case series.

Brain and language
2025

Delayed progressive apraxia of speech: A novel clinical entity distinct from primary progressive aphasia - A descriptive case series.

Journal of the neurological sciences
2025

The role of structural and functional parameters in designing pathology-specific tDCS protocols for primary progressive aphasia.

Alzheimer's research &amp; therapy
2025

Network changes associated with right anterior temporal lobe atrophy: insight into unique symptoms.

Brain communications
2025

Communication Strategies Used in Primary Progressive Aphasia: A Scoping Review.

Dementia (London, England)
2025

Advances in Neuromodulation Techniques for Aphasia Rehabilitation: A Comprehensive Review.

Medical science monitor : international medical journal of experimental and clinical research
2025

Multiparametric MRI-based biomarkers in the non-fluent and semantic variants of primary progressive aphasia.

Journal of neurology
2025

Mapping Primary Progressive Aphasia Best Practices to a Person-Centered Video Biopic.

American journal of speech-language pathology
2025

Survival rates in frontotemporal dementia and Alzheimer's disease.

Neurodegenerative disease management
2025

Validation of criteria for frontotemporal dementia with right anterior temporal lobe predominance.

Alzheimer's &amp; dementia : the journal of the Alzheimer's Association
2025

Interpreting Addenbrooke's Cognitive Examination-III Scores in Dementia: Performance Distributions and Clinically Meaningful Change.

European journal of neurology
2025

A Case Study of a Multilingual Individual with Primary Progressive Aphasia: Diagnostic Considerations and Implications for Language Representation.

Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists
2025

Let's Chat About Spoken Discourse: A Tutorial to Support Use of Spoken Discourse Analysis When Providing Aphasia Clinical Services.

American journal of speech-language pathology
2025

Profiles of Vulnerability to Financial Exploitation in the Degenerative Dementias.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
2025

Linguistic effects of transcranial Direct Current Stimulation (tDCS) in patients with primary progressive aphasia: A systematic review and meta-analysis of randomised controlled trials.

Neuroscience and biobehavioral reviews
2025

"Assessing relationship between blood MAPT methylation levels and clinical expression in Frontotemporal Dementia".

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Decline in activities of daily living in the rarer dementias.

General psychiatry
2025

The neural basis of frontotemporal dementia (FTD): insights from ALE meta-analyses of four FTD subtypes encompassing 8,057 patients.

medRxiv : the preprint server for health sciences
2025

Multiplex connectomics reveal altered networks in frontotemporal dementia: A multisite study.

Network neuroscience (Cambridge, Mass.)
2025

Comparing Two Connected Speech Tasks in Greek Speakers With the Logopenic Variant of Primary Progressive Aphasia and Alzheimer's Disease.

American journal of speech-language pathology
2025

The Pattern of Phonological, Semantic, and Circumlocution Naming Errors for Nouns and Verbs in Primary Progressive Aphasia.

Aphasiology
2025

[Primary progressive aphasia in the neurologist practice].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2025

[Phenotypes and epidemiology of frontotemporal dementia in Iceland].

Laeknabladid
2025

'Dementia has got two faces': grief as an experience of holding on and letting go for people living with primary progressive aphasia and posterior cortical atrophy.

Aging &amp; mental health
2025

Safety and Efficacy of Different Therapeutic Interventions for Primary Progressive Aphasia: A Systematic Review.

Journal of clinical medicine
2025

Transcranial direct current stimulation over the temporal-parietal junction yields no lexical-semantic effects in logopenic primary progressive aphasia: a double-blind sham-controlled study.

NeuroImage. Clinical
2026

Navigating the diagnosis and treatment of primary progressive aphasia: Lived experience of a rural patient.

Dementia (London, England)
2025

Cognitive stimulation in non-memory led dementias: A scoping review.

Dementia (London, England)
2025

ANXA11 Mutations in the FTD Spectrum: A Novel Finding in a Patient With Semantic Variant Primary Progressive Aphasia.

European journal of neurology
2025

Knowledge, attitude, and practice of neurologists toward primary progressive aphasia in Indonesia.

Journal of Alzheimer's disease : JAD
2025

Potential scalp acupuncture and brain stimulation targets for common neurological disorders: evidence from neuroimaging studies.

Chinese medicine
2025

The cerebellum in frontotemporal dementia: From neglected bystander to potential neuromodulatory target. A narrative review.

Neuroscience and biobehavioral reviews
2025

Nation-wide Japanese FTD consortium FTLD-J: Utility of case review meetings.

International psychogeriatrics
2025

iSupport for rare dementias: a mixed-methods non-randomised feasibility study of an online self-help programme for carers.

Pilot and feasibility studies
2025

Role of pause duration in primary progressive aphasia.

Aphasiology
2025

Survival Differences Between Individuals With Typical and Atypical Phenotypes of Alzheimer Disease.

Neurology
2025

Partial volume effect correction impairs the diagnostic utility of [18F]-THK-5351 PET in nonfluent-agrammatic variant primary progressive aphasia.

NeuroImage. Clinical
2025

Diagnosing neurodegenerative disorders using retina as an external window: A systematic review of OCT-MRI correlations.

Journal of Alzheimer's disease : JAD
2025

Theory of mind deficits in non-fluent primary progressive aphasia.

Cortex; a journal devoted to the study of the nervous system and behavior
2025

Primary Tauopathy With Logopenic/Semantic Mixed Progressive Aphasia and Frontotemporal Dementia-like Behavior.

Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology
2025

Progranulin deficiency in the brain: the interplay between neuronal and non-neuronal cells.

Translational neurodegeneration
2025

Addressing Phonological Deficit in Primary Progressive Aphasia With Behavioral Intervention and Transcranial Direct Current Stimulation.

Journal of speech, language, and hearing research : JSLHR
2025

The relevance and challenges of cross-cultural studies in primary progressive aphasia.

Journal of the neurological sciences
2025

Connected Speech Alterations and Progression in Patients With Primary Progressive Aphasia Variants.

Neurology
2025

Insights into primary progressive aphasia.

Journal of neurology
2025

Cognitive Phenotyping and Interpretation of Alzheimer Blood Biomarkers.

JAMA neurology
2025

Utilization of resting-state electroencephalography spectral power in convolutional neural networks for classification of primary progressive aphasia.

Neuroimage. Reports
2026

Neuropsychiatric symptoms in sporadic Creutzfeldt-Jakob disease.

Brain : a journal of neurology
2025

Primary Progressive Aphasias: Diagnosis and Treatment.

Brain sciences
2025

Efficacy of Communication Bridge-2 for primary progressive aphasia: A randomized controlled trial of communication intervention.

Alzheimer's &amp; dementia : the journal of the Alzheimer's Association
2025

Case report: Behavioral variant FTD confounding a language variant FTD in a case of PSP-CBS.

Frontiers in dementia
2025

The review of the long-term health risks associated with vasectomy.

International journal of impotence research
2025

Cerebellar dysfunction in frontotemporal dementia: intra-cerebellar pathology and cerebellar network degeneration.

Journal of neurology
2025

Distinct cerebral perfusion patterns and linguistic profiles in Alzheimer's disease-related primary progressive aphasia.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Unveiling the enigmatic: Primary progressive apraxia of speech - A case report.

Clinical parkinsonism &amp; related disorders
2025

Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders.

Molecular neurodegeneration
2025

Hemispheric asymmetry in neurodegenerative diseases.

Handbook of clinical neurology
2025

Behavioral and neural effects of temporoparietal high-definition transcranial direct current stimulation in logopenic variant primary progressive aphasia: a preliminary study.

Frontiers in psychology
2025

Brain Perfusion, Atrophy, and Dopaminergic Changes in Amyloid Negative Logopenic Primary Progressive Aphasia.

Scientific reports
2025

Cognitive profiles in primary progressive aphasia variants: A cross-cultural Australian and Spanish investigation.

Journal of the neurological sciences
2025

Semantic variant primary progressive aphasia with ANXA11 p.D40G.

Alzheimer's &amp; dementia : the journal of the Alzheimer's Association
2024

A Regression Framework for Predicting Cognitive Decline in Frontotemporal Dementia using Recurrent Neural Networks.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference
2024

Artificial Intelligence Based Hierarchical Classification of Frontotemporal Dementia.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference
2025

Validation of the Cognitive-Emotional Perspective Taking test in patients with neurodegeneration.

Journal of Alzheimer's disease : JAD
2025

Feasibility of home-based transcranial direct current stimulation combined with personalized word retrieval for improving naming in primary progressive aphasia.

Frontiers in neurology
2025

The Functional Origin of Oral Word Production Deficits in the Logopenic Variant of Primary Progressive Aphasia: A Systematic Review.

Brain sciences
2025

Effects of single-session repetitive transcranial magnetic stimulation to identify the optimal brain target in primary progressive aphasia.

Journal of Alzheimer's disease : JAD
2025

Frontotemporal dementia subtyping using machine learning, multivariate statistics and neuroimaging.

Brain communications
2025

The use of low-density EEG for the classification of PPA and MCI.

Frontiers in human neuroscience
2025

Behavioural changes in frontotemporal dementia and their cognitive and neuroanatomical correlates.

Brain : a journal of neurology
2025

Multi-parametric [18F]PI-2620 tau PET/MRI for the phenotyping of different Alzheimer's disease variants.

European journal of nuclear medicine and molecular imaging
2025

Predicting survival rate by plasma biomarkers and clinical variables in syndromes associated with frontotemporal lobar degeneration.

Alzheimer's &amp; dementia : the journal of the Alzheimer's Association
2025

The Cortical Asymmetry Index for subtyping dementia patients.

European radiology
2025

aFTLD-U presenting with primary progressive aphasia suggestive of non-fluent type with apraxia of speech.

Neurocase
Ver todos os 1.226 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Afasia primária progressiva.

É de uma associação que acompanha esta doença? Fale com a gente →

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Afasia primária progressiva e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

É um distúrbio neurodegenerativo caracterizado pelo declínio primário da linguagem com preservação relativa de outras funções mentais no início. Ela integra o espectro das demências frontotemporais e costuma iniciar na idade adulta.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

10 publicações do grafo RarasNet (PubMed) · 6 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. ORPHA:95432
    Orphanet
  2. GARD:8541
    GARD (NIH)
  3. Q18767
    Wikidata

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (s.d.). Afasia primária progressiva. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/afasia-primaria-progressiva

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Afasia primária progressiva
Compêndio · Raras BR

Afasia primária progressiva

ORPHA:95432 · MONDO:0019806
Prevalência
1-9 / 100 000
Herança
Multigenic/multifactorial, Not applicable
CID-11
Ensaios
34 ativos
Início
Adult
Prevalência
7.0 (Worldwide)
MedGen
UMLS
C0282513
EuropePMC
Wikidata
Papers 10a

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Indexação biomédica
fonte: MeSH (NLM)
Dado público estruturado
fonte: Wikidata
Rara